Loading company…
Phase Advance provides predictive analytics for pharmaceutical and biotechnology drug development.
Founded in 2024 and based in Dallas, US, Phase Advance provides predictive analytics for drug development. Its models assess patient responses, biomarkers, dosages, and drug performance for pharmaceutical and biotechnology firms. In October 2025, it raised an undisclosed amount of venture funding from QNova Capital to advance AI-driven drug development and reduce reliance on animal models.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in